Monopar Therapeutics annual current ratio
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Monopar Therapeutics Current Ratio Growth & History (MNPR)
Monopar Therapeutics's current ratio was 51.35 for fiscal 2025.
View full Monopar Therapeutics company overviewMonopar Therapeutics annual current ratio history
| Fiscal year | Period ended | Current ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 51.35 | 39.88 | +347.54% |
| 2024 | 2024-12-31 | 11.47 | 7.30 | +175.01% |
| 2023 | 2023-12-31 | 4.17 | −0.04 | −0.84% |
| 2022 | 2022-12-31 | 4.21 | −8.78 | −67.59% |
| 2021 | 2021-12-31 | 12.98 | −1.29 | −9.06% |
| 2020 | 2020-12-31 | 14.28 | −3.99 | −21.85% |
| 2019 | 2019-12-31 | 18.27 | 0.12 | +0.65% |
| 2018 | 2018-12-31 | 18.15 | −11.13 | −38.01% |
| 2017 | 2017-12-31 | 29.28 | −3.20 | −9.85% |
| 2016 | 2016-12-31 | 32.48 | — | — |
Monopar Therapeutics quarterly current ratio
Q4.16
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Current ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 33.56 | −0.38 | −1.13% |
| Q1 2026 | 2026-03-31 | 56.04 | 19.13 | +51.82% |
| Q4 2025 | 2025-12-31 | 51.35 | 39.88 | +347.54% |
| Q3 2025 | 2025-09-30 | 56.10 | — | — |
| Q2 2025 | 2025-06-30 | 33.94 | — | — |
| Q1 2025 | 2025-03-31 | 36.92 | — | — |
| Q4 2024 | 2024-12-31 | 11.47 | 7.30 | +175.01% |
| Q4 2023 | 2023-12-31 | 4.17 | −0.04 | −0.84% |
| Q3 2023 | 2023-09-30 | 4.32 | −3.18 | −42.41% |
| Q2 2023 | 2023-06-30 | 4.12 | −3.50 | −45.92% |
| Q1 2023 | 2023-03-31 | 4.08 | −12.69 | −75.67% |
| Q4 2022 | 2022-12-31 | 4.21 | −8.78 | −67.59% |
| Q3 2022 | 2022-09-30 | 7.51 | — | — |
| Q2 2022 | 2022-06-30 | 7.61 | — | — |
| Q1 2022 | 2022-03-31 | 16.77 | −15.28 | −47.67% |
| Q4 2021 | 2021-12-31 | 12.98 | −1.29 | −9.06% |
| Q1 2021 | 2021-03-31 | 32.05 | 3.37 | +11.77% |
| Q4 2020 | 2020-12-31 | 14.28 | −3.99 | −21.85% |
| Q3 2020 | 2020-09-30 | 29.66 | 19.10 | +180.80% |
| Q2 2020 | 2020-06-30 | 22.21 | 10.26 | +85.89% |
| Q1 2020 | 2020-03-31 | 28.67 | 17.72 | +161.72% |
| Q4 2019 | 2019-12-31 | 18.27 | 0.12 | +0.65% |
| Q3 2019 | 2019-09-30 | 10.56 | −14.73 | −58.24% |
| Q2 2019 | 2019-06-30 | 11.95 | −11.72 | −49.52% |
| Q1 2019 | 2019-03-31 | 10.96 | −17.77 | −61.87% |
| Q4 2018 | 2018-12-31 | 18.15 | −11.13 | −38.01% |
| Q3 2018 | 2018-09-30 | 25.29 | — | — |
| Q2 2018 | 2018-06-30 | 23.67 | — | — |
| Q1 2018 | 2018-03-31 | 28.73 | — | — |
| Q4 2017 | 2017-12-31 | 29.28 | −3.20 | −9.85% |
| Q4 2016 | 2016-12-31 | 32.48 | — | — |
Monopar Therapeutics current ratio trends
Over the last five fiscal years, Monopar Therapeutics's current ratio increased from 14.28 to 51.35, a change of 37.08. The latest reported quarter, Q2 2026, shows 33.56.
About the metric
What the current ratio means
The current ratio compares short-term assets with obligations due within roughly one year. A higher ratio generally indicates more short-term balance-sheet coverage, but normal levels vary by industry and business model.
Calculation and source
How the current ratio is calculated
TickerStat calculates the current ratio as SEC-reported current assets divided by SEC-reported current liabilities for the same balance-sheet date. Periods without a positive current-liability value are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Monopar Therapeutics source filings ↗